| |
Training set
| | |
Test
|
Sets
| | |
|---|
|
Cohort
|
NKI2+EMC+NCH
|
UPP
|
JRH-2
|
CAL
|
Kreike
|
UNC248
|
Loi
|
|---|
|
Cohort size
|
186
|
34
|
24
|
46
|
97
|
85
|
40
|
|
Annotated
|
183
|
31
|
24
|
46
|
71
|
80
|
34
|
|
Good prognosis (%)
|
59
|
81
|
75
|
67
|
76
|
74
|
76
|
|
Poor prognosis (%)
|
41
|
19
|
25
|
33
|
24
|
26
|
24
|
|
Chemotherapy (%)
|
0
|
0
|
0
|
67
|
0
|
66
|
0
|
|
MDA
| | | | | | | |
|
NPV (%)
|
74
|
92
|
93
|
69
|
83
|
74
|
100
|
|
PPV (%)
|
55
|
28
|
56
|
35
|
29
|
27
|
40
|
|
SE (%)
|
69
|
83
|
83
|
53
|
71
|
38
|
100
|
|
SP (%)
|
61
|
48
|
78
|
52
|
44
|
63
|
54
|
|
MDAhet
| | | | | | | |
|
NPV (%)
|
80
|
100
|
100
|
100
|
85
|
92
|
100
|
|
PPV (%)
|
51
|
30
|
37
|
45
|
29
|
36
|
35
|
|
SE (%)
|
84
|
100
|
100
|
100
|
76
|
90
|
100
|
|
SP (%)
|
44
|
44
|
44
|
42
|
41
|
42
|
42
|
|
NPV at 4 years (%)
|
83
|
100
|
100
|
100
|
88
|
93
|
100
|
|
PPV at 4 years (%)
|
42
|
24
|
33
|
35
|
25
|
45
|
35
|
|
SE at 4 years (%)
|
83
|
100
|
100
|
100
|
79
|
88
|
100
|
|
SP at 4 years (%)
|
44
|
42
|
43
|
37
|
40
|
45
|
43
|
|
LN
| | | | | | | |
|
NPV (%)
|
61
|
84
|
NA
|
85
|
NA
|
85
|
76
|
|
PPV (%)
|
50
|
30
|
NA
|
46
|
NA
|
37
|
0a
|
|
SE (%)
|
27
|
50
|
NA
|
80
|
NA
|
71
|
0a
|
|
SP (%)
|
81
|
70
|
NA
|
55
|
NA
|
58
|
100a
|
|
NPV at 4 years (%)
|
67
|
88
|
NA
|
90
|
NA
|
82
|
77
|
|
PPV at 4 years (%)
|
39
|
37
|
NA
|
38
|
NA
|
47
|
0a
|
|
SE at 4 years (%)
|
25
|
84
|
NA
|
85
|
NA
|
69
|
0a
|
|
SP at 4 years (%)
|
80
|
74
|
NA
|
53
|
NA
|
60
|
100a
|
-
aLoi's cohort consists only of LN- samples. The table summarises performance indicators of the seven-gene MDAhet classifier and lymph node status (LN) across oestrogen receptor negative (ER-) training and test sets. For each cohort, we also give the number of tumours (cohort size), number of clinically annotated tumours (annotated), the percentage of good and poor prognosis patients (as defined by disease-specific death or distant metastasis event) and the percentage of patients treated with chemotherapy. NPV, PPV, SE and SP are evaluated at four years and at end of study. NPV, negative predictive value (precision for good prognosis); PPV, positive predictive value (precision for poor prognosis); SE, sensitivity; SP, specificity.
